Table 1.
Variable | No anxiety (N = 812) | Anxiety (N = 190) | p value |
---|---|---|---|
Age (M, SD) | 78.3 (8.0) | 78.4 (8.4) | .94 |
Race (% African American) | 30.3% | 22.6% | .04 |
Marital status (% married) | 20.8% | 22.1% | .70 |
Education (M, SD) | 9.9 (4.7) | 9.9 (6.9) | .94 |
Vision (% with problem) | 15.6% | 22.1% | .03 |
Hearing (% with problem) | 20.1% | 24.7% | .16 |
Number of diseases (M, SD) | 2.0 (1.4) | 2.5 (1.4) | .01 |
BMI (M, SD) | 28.5 (6.8) | 27.8 (6.8) | .23 |
Summary performance score (M, SD) | 6.1 (3.2) | 5.4 (3.4) | <.001 |
Depressive symptoms (% scoring ≥ 10) | 23.6% | 66.3% | <.001 |
Benzodiazepine use (M, SD) | 7.1% | 15.8% | <.001 |
Physical activity (% active) | 14.9% | 11.9% | .19 |
Emotional support (% had enough in prior year) | 74.9% | 47.4% | < .001 |
Number of domains of disability (M, SD) | 2.98 (0.86) | 3.36 (0.78) | < .001 |
Psychotropic medication use | 16.5% | 27.9% | < .001 |
Note: Psychotropic medications include barbituates, monamine oxidase inhibitors, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, trazadone, and tricyclics, and were used on a routine or prn basis.